3-hydroxyflavone has been researched along with Acute Myelogenous Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Çiçek, SS; Galarza Pérez, M; Jöhrer, K; Kircher, B | 1 |
| Fu, HL; He, MH; Liang, XX; Lin, JC; Shi, F; Shu, G; Yin, L; Yuan, ZX; Zhang, Q; Zhao, L | 1 |
2 other study(ies) available for 3-hydroxyflavone and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from
Topics: Cell Line, Tumor; Flavones; Flavonols; Lamiaceae; Leukemia, Myeloid, Acute; Lignans; Multiple Myeloma; Phenols | 2022 |
Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Flavonols; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oncogene Proteins, Fusion; Proteolysis; Signal Transduction; STAT1 Transcription Factor; Tretinoin | 2018 |